An Introduction to Prostate Cancer
The management of prostate cancer has evolved rapidly over the last decade. There are now several approved treatments in the castration-resistant treatment setting, delivering significant benefits like overall survival rate. The androgen receptor-targeting agents are also now proving effective in the hormone-sensitive setting.
Browse the content below where leading experts, discuss the latest data in video interviews and short articles from our conference hub and browse the selection of peer-reviewed articles from our journal portfolio. If you’re looking to learn more about the impact of these developments on patient outcomes, our educational activities are a great resource.
Our supporting partners do not constitute an endorsement of the content on this page.
Prostate Cancer Content
Arnulf Stenzl: Highlights from EAU23!
touchONCOLOGY caught up with the Secretary General of the European Association of Urology (EAU), Prof Arnulf Stenzl, to discuss some of the key advances from the conference. He focusses this interview on prostate cancer, early detection, systemic therapy, new therapies in castration-resistant prostate cancer and the latest knowledge in the use of PARP inhibitors. Topics […]
Axel Merseburger: Current advances in prostate cancer treatment options and what we might expect in the next 5 years
Our Editor-in-Chief Axel Merseburger (Lübeck University, Lübeck, Germany) discusses the most important recent advances in the treatment landscape for prostate cancer, including screening using MRI and PSMA PET-CT scans, and triplet therapies using hormone therapy and PARP inhibitors. He also takes a look to the future, discussing developments he hopes to see in early detection, […]
Axel Merseburger: Highlights of EAU23
Our Editor-in-Chief Axel Merseburger (Lübeck University, Lübeck, Germany) discusses key data from this year’s European Association of Urology annual meeting (EAU23) in the field of prostate cancer. He discusses results from the LuTectomy trial, the 15-year update of the ProtecT trial and the PROBASE trial. Question: Please summarize the most important presentations and data from […]
Fred Saad, ESMO 2022: Highlights in prostate cancer – Phase 3 trials in the STAMPEDE platform protocol
Prof. Fred Saad (University of Montreal Hospital Centre, Université de Montréal, Quebec, Canada) joins touchONCOLOGY to discuss clinical trial highlights in prostate cancer presented at EMSO 2022. He highlights the results from one of the phase 3 STAMPEDE trials, investigating combination abiraterone and enzalutamide or abiraterone and prednisolone, for metastatic hormone sensitive prostate cancer (mHSPC), […]
Fred Saad, ESMO 2022: Phase 3 PROpel trial of abiraterone and olaparib for patients with prostate cancer – Biomarker analysis and updated results
In the PROpel trial, abiraterone and olaparib significantly prolonged radiographic progression free survival in patients with metastatic castration-resistant prostate cancer. Prof. Fred Saad (University of Montreal Hospital Centre, Université de Montréal, Quebec, Canada) joins touchONCOLOGY to discuss the biomarker analysis from the primary analysis, and updated overall survival and safety data. The abstract entitled ‘Biomarker […]
Is Triple Therapy the New Standard for Metastatic Hormone-sensitive Prostate Cancer?
touchREVIEWS in Oncology & Haematology 2022;18(2):120-4 DOI: https://doi.org/10.17925/OHR.2022.18.2.120
Androgen deprivation therapy (ADT) has been the cornerstone of the treatment of metastatic prostate carcinoma for over 70 years, ever since Huggins and Hodges first treated men with prostate carcinoma with orchidectomy or oestrogen injection in 1941.1 However, the treatment landscape of metastatic hormone-sensitive prostate cancer (mHSPC) has changed rapidly over the past decade, with level […]
Axel Merseburger, ASCO 2022: Highlights in prostate cancer clinical trials – Phase 3 SHR3680 trial, ENZAMET trial, MAGNITUDE trial, PROPEL trial, phase 2 lutetium 177 trial, VISION trial
ASCO 2022 showcased many important studies in prostate cancer. Prof. Axel Merseburger (Department of Urology, University of Lubeck, Germany), touchONCOLOGY’s Editor-in-Chief, joins us to share his highlights. In this interview he discusses: the phase 3 trial of SHR3680 versus bicalutamide in combination with androgen deprivation therapy in patients with prostate cancer (0:40); the interim overall […]
PARP inhibitors in prostate cancer: New combinations, new possibilities
Watch leading specialists discuss new PARP inhibitor combinations for the treatment of advanced prostate cancer
- Analyse the mechanism of action of PARP inhibitors and the biological and clinical rationale for PARP inhibitor combinations in the treatment of advanced prostate cancer
- Discuss key data from clinical trials with PARP inhibitor combinations in the management of advanced prostate cancer
- Recognize the potential for extended benefit of PARP inhibitor combinations in advanced prostate cancer beyond HRR gene mutations
Sexual Function of Men Undergoing Active Prostate Cancer Treatment Versus Active Surveillance: Results of the Europa Uomo Patient Reported Outcome Study
touchREVIEWS in Oncology & Haematology. 2022;18(1):88–94 DOI: https://doi.org/10.17925/OHR.2022.18.1.88
Treatment for prostate cancer impacts the health-related quality of life of men. Patient-reported outcome (PRO) data from prospective, investigator-initiated clinical trials have shown that effects are seen on the urinary, bowel, and sexual function domains and, to a lesser extent, on the general quality of life (QoL) of men.1–5 In these clinical studies, patients reported […]
Journal articles and more to your inbox
Get the latest clinical insights from touchONCOLOGYSign me up!